<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02989207</url>
  </required_header>
  <id_info>
    <org_study_id>160807</org_study_id>
    <secondary_id>15/LO/1810</secondary_id>
    <nct_id>NCT02989207</nct_id>
  </id_info>
  <brief_title>Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans</brief_title>
  <acronym>PEACE</acronym>
  <official_title>Comparing Surgical Approaches to Treat Black African and Africa-Caribbean Patients With Uncontrolled Primary Open Angle Glaucoma: A Randomised Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to perform a randomised feasibility trial preceding a large prospective randomised&#xD;
      controlled trial (RCT) comparing three surgical methods - trabeculectomy with Mitomycin C&#xD;
      (MMC), primary Baerveldt tube with MMC and Baerveldt tube without MMC - in black&#xD;
      African/African Caribbean patients with Primary Open Angle Glaucoma (POAG) living in London.&#xD;
&#xD;
      The UK Office of National Statistics estimated that among the population of England in 2007,&#xD;
      approximately 4.3% were of African/African-Caribbean background, while in large cities such&#xD;
      as London and Birmingham about 20% of the population is of African/African-Caribbean origin.&#xD;
      For eye units in these cities, managing glaucoma in this population is challenging and we&#xD;
      need to identify a better alternative to our current standard surgical treatment.&#xD;
&#xD;
      There is now evidence from one RCT which shows better overall outcomes from tube surgery in&#xD;
      comparison to trabeculectomy for glaucoma. However, this study did not address black&#xD;
      populations specifically and did not address the potential role of MMC in tube surgery.&#xD;
&#xD;
      This feasibility study will enable us to design a fully powered RCT with the aim of&#xD;
      determining how best to optimise the surgical treatment of POAG in black populations, by&#xD;
      comparing outcomes in three types of glaucoma surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An audit performed at St Thomas's Hospital in 2008 showed that 52 trabeculectomy and 50&#xD;
      Baerveldt tube procedures were done in one year, with 60% of the patients being of 'black'&#xD;
      ethnicity. This audit provides the basis for teh recruitment target. Assuming that the&#xD;
      majority of the trabeculectomies performed were for POAG then most of these 'black' patients&#xD;
      would have been eligible for the trial.&#xD;
&#xD;
      Primary Tube versus Trabeculectomy Study (PTVT) St Thomas' Hospital is the leading recruiting&#xD;
      centre for this multinational study. The investigators have recruited over 50 patients in the&#xD;
      last 2 years despite the lack of a dedicated research team. The trial retention rate has also&#xD;
      been very good with less than 5% loss to follow-up rates.&#xD;
&#xD;
      Patient Feedback and Involvement The proposed research was reviewed in a feedback session in&#xD;
      2012 with 5 black African-Caribbean/African patients with glaucoma attending St Thomas'&#xD;
      Hospital. All were very positive about the potential trial and all understood that there is a&#xD;
      'unique' problem for glaucoma surgery in this group of patients. Suggestions for the trial&#xD;
      included more emphasis on the importance of treatment for glaucoma, disseminating information&#xD;
      about the trial in community centres, and the possibility of expert patients who can act as&#xD;
      patient advocates and help with recruitment in the glaucoma clinics and present the study in&#xD;
      local community centres.&#xD;
&#xD;
      Feasibility study This protocol is for a randomised feasibility trial which will compare&#xD;
      standard treatment (trabeculectomy with MMC) with primary Baerveldt tube surgery with or&#xD;
      without MMC in black African/African-Caribbean patients with POAG living in London. The study&#xD;
      will look at the feasibility of recruitment for a proposed larger scale RCT and will also&#xD;
      help the investigators to refine the methodology for the proposed trial in terms of outcome&#xD;
      measures and analysis. It will also help the investigators to recruit a patient user group&#xD;
      for input into the conduct and monitoring of the main trial.&#xD;
&#xD;
      Information the study will provide&#xD;
&#xD;
      The investigators are conducting this feasibility study in order to get an estimate of the&#xD;
      likely recruitment rate for the main study and to collect information that will help the&#xD;
      investigators to refine the outcome measures for the main study and to allow a valid&#xD;
      calculation of the sample size needed for a definitive study to answer the primary research&#xD;
      question. The investigators will use questionnaires to gather data on patients' quality of&#xD;
      life for health economic analysis but it is also our hope that the questionnaires will give&#xD;
      the investigators information on the perspectives of patients, including their preferences.&#xD;
      This feasibility study will help the investigators to explore how they can gather useful&#xD;
      information on the patient perspective.&#xD;
&#xD;
      The feasibility study will also inform their planning for the main trial and data management&#xD;
      and help them to develop their community engagement and recruitment strategies, including&#xD;
      theri strategy for publicising the trial and enhancing recruitment. In addition, the&#xD;
      investigators intend to use the feasibility study to recruit a patient representative group&#xD;
      for input into the conduct and monitoring of the proposed main study.&#xD;
&#xD;
      Risks and benefits The potential risks and benefits for patients participating in the&#xD;
      feasibility study are similar to those for standard clinical care. All participants will have&#xD;
      been identified as in need of glaucoma drainage surgery. Both trabeculectomy (currently as&#xD;
      first line treatment) and Baerveldt tube surgery (currently as second line treatment) are in&#xD;
      routine use for the treatment of POAG. Evidence on the beneficial effect of MMC is equivocal.&#xD;
      First line treatment with Baerveldt tube surgery may be associated with less failure and&#xD;
      complications than first line treatment by trabeculectomy but there is as yet no definitive&#xD;
      evidence on this question that is specific to the population included in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate:</measure>
    <time_frame>6 months</time_frame>
    <description>The number of potential participants enrolled over a set time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate</measure>
    <time_frame>6 months</time_frame>
    <description>Eyes that have not failed and are not on supplemental medical therapy are considered complete successes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure rate</measure>
    <time_frame>6 months</time_frame>
    <description>IOP &gt;21 mmHg or not reduced by 20% below baseline on two consecutive follow-up visits&#xD;
Additional glaucoma surgery&#xD;
Loss of vision.&#xD;
IOP &lt;5 mmHg on two consecutive follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of extra unscheduled clinic visits and unplanned procedures</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss to follow-up rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates to the self-report</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Trabeculectomy with Mitomycin-C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The current standard surgical treatment for glaucoma remains trabeculectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baerveldt tube surgery with Mitomycin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It consists of a tube, draining aqueous humour to a plate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baerveldt tube surgery without Mitomycin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>It consists of a tube, draining aqueous humour to a plate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes</description>
    <arm_group_label>Trabeculectomy with Mitomycin-C</arm_group_label>
    <other_name>Trabeculectomy with Mitomycin-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baerveldt tube surgery</intervention_name>
    <description>All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.</description>
    <arm_group_label>Baerveldt tube surgery with Mitomycin C</arm_group_label>
    <arm_group_label>Baerveldt tube surgery without Mitomycin C</arm_group_label>
    <other_name>Baerveldt tube surgery with Mitomycin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin-C</intervention_name>
    <description>This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery</description>
    <arm_group_label>Baerveldt tube surgery with Mitomycin C</arm_group_label>
    <arm_group_label>Trabeculectomy with Mitomycin-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to understand the information sheet and give informed consent.&#xD;
&#xD;
          -  Black African Caribbean or African (defined as a person having origins in any of the&#xD;
             black racial groups of Africa). The identification of African or African-Caribbean&#xD;
             ethnicity will be based on patients' self-reported ethnicity classification in their&#xD;
             NHS case notes. In our recent audit, almost 90% of the case notes had data on&#xD;
             patients' self-reported ethnicity.&#xD;
&#xD;
          -  Age 18 to 85 years, inclusive. Inclusion criteria for study eye&#xD;
&#xD;
        All of the criteria listed below must be present in the study eye in order for the patient&#xD;
        to be eligible for enrolment in the study:&#xD;
&#xD;
        • Glaucoma that is uncontrolled on tolerated medical therapy with IOP ≥18 mmHg and ≤40 mmHg&#xD;
        in the study eye.&#xD;
&#xD;
        • No previous incisional ocular surgery in the study eye except for: i) Clear corneal&#xD;
        phacoemulsification surgery. ii) Previous conjunctival sparing minimally invasive glaucoma&#xD;
        surgeries (MIGS) more than 6 months ago. This may include procedures that do not involve&#xD;
        the conjunctiva such as Hydrus Microstent, iStent and endoscopic cyclophotocoagulation&#xD;
        (ECP) laser.&#xD;
&#xD;
        The authors do not think it likely that pseudophakia will influence the outcomes but&#xD;
        randomisation will be stratified by lens status to ensure balance in the treatment arms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
        Patients are ineligible to participate in the study where any of the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Any inclusion criteria not met.&#xD;
&#xD;
          -  Pregnant or nursing women (or planning pregnancy).&#xD;
&#xD;
          -  Unwilling or unable to give informed consent, unwilling to accept randomisation, or&#xD;
             unable to return for scheduled protocol visits.&#xD;
&#xD;
          -  Ongoing participation in other interventional clinical trials. Exclusion criteria for&#xD;
             study eye&#xD;
&#xD;
        The patient may not be entered into the study if any of the following exclusion criteria&#xD;
        are present in the study eye:&#xD;
&#xD;
          -  No light perception vision.&#xD;
&#xD;
          -  Active diabetic retinopathy.&#xD;
&#xD;
          -  Secondary glaucomas.&#xD;
&#xD;
          -  Unwilling to discontinue contact lens use after surgery.&#xD;
&#xD;
          -  Conjunctival scarring from prior ocular trauma or cicatrizing disease (e.g. Stevens&#xD;
             Johnson syndrome, ocular pemphigoid) precluding a superior trabeculectomy.&#xD;
&#xD;
          -  Functionally significant cataract likely to require surgery within 6 months of&#xD;
             glaucoma surgery.&#xD;
&#xD;
          -  Previous complicated cataract surgery in the study eye.&#xD;
&#xD;
          -  Need for glaucoma surgery combined with other ocular procedures (i.e. cataract&#xD;
             surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for&#xD;
             additional ocular surgery.&#xD;
&#xD;
          -  Iris neovascularization or proliferative retinopathy.&#xD;
&#xD;
          -  Iridocorneal endothelial syndrome.&#xD;
&#xD;
          -  Epithelial or fibrous downgrowth.&#xD;
&#xD;
          -  Chronic or recurrent uveitis.&#xD;
&#xD;
          -  Steroid-induced glaucoma.&#xD;
&#xD;
          -  Severe posterior blepharitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Sheng Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheng Lim, MD</last_name>
    <phone>+442071884885</phone>
    <email>shenglim@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Jones</last_name>
    <phone>+442071884885</phone>
    <email>stephanie.jones@gstt.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Sheng Lim, MD</last_name>
      <phone>+442071884885</phone>
      <email>shenglim@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Jones, BSc</last_name>
      <phone>+442071884885</phone>
      <email>stephanie.jones@gsst.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Trabeculectomy</keyword>
  <keyword>Glaucoma drainage implant</keyword>
  <keyword>Africa and Africa-Caribbean</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02989207
org study id: 160807
secondary id: 15/LO/1810
nct id: NCT02989207
lead sponsor: 
has dmc: Yes
The aim is to perform a randomised feasibility trial preceding a large prospective randomised
      controlled trial (RCT) comparing three surgical methods - trabeculectomy with Mitomycin C
      (MMC), primary Baerveldt tube with MMC and Baerveldt tube without MMC - in black
      African/African Caribbean patients with Primary Open Angle Glaucoma (POAG) living in London.

      The UK Office of National Statistics estimated that among the population of England in 2007,
      approximately 4.3% were of African/African-Caribbean background, while in large cities such
      as London and Birmingham about 20% of the population is of African/African-Caribbean origin.
      For eye units in these cities, managing glaucoma in this population is challenging and we
      need to identify a better alternative to our current standard surgical treatment.

      There is now evidence from one RCT which shows better overall outcomes from tube surgery in
      comparison to trabeculectomy for glaucoma. However, this study did not address black
      populations specifically and did not address the potential role of MMC in tube surgery.

      This feasibility study will enable us to design a fully powered RCT with the aim of
      determining how best to optimise the surgical treatment of POAG in black populations, by
      comparing outcomes in three types of glaucoma surgery.
An audit performed at St Thomas's Hospital in 2008 showed that 52 trabeculectomy and 50
      Baerveldt tube procedures were done in one year, with 60% of the patients being of 'black'
      ethnicity. This audit provides the basis for teh recruitment target. Assuming that the
      majority of the trabeculectomies performed were for POAG then most of these 'black' patients
      would have been eligible for the trial.

      Primary Tube versus Trabeculectomy Study (PTVT) St Thomas' Hospital is the leading recruiting
      centre for this multinational study. The investigators have recruited over 50 patients in the
      last 2 years despite the lack of a dedicated research team. The trial retention rate has also
      been very good with less than 5% loss to follow-up rates.

      Patient Feedback and Involvement The proposed research was reviewed in a feedback session in
      2012 with 5 black African-Caribbean/African patients with glaucoma attending St Thomas'
      Hospital. All were very positive about the potential trial and all understood that there is a
      'unique' problem for glaucoma surgery in this group of patients. Suggestions for the trial
      included more emphasis on the importance of treatment for glaucoma, disseminating information
      about the trial in community centres, and the possibility of expert patients who can act as
      patient advocates and help with recruitment in the glaucoma clinics and present the study in
      local community centres.

      Feasibility study This protocol is for a randomised feasibility trial which will compare
      standard treatment (trabeculectomy with MMC) with primary Baerveldt tube surgery with or
      without MMC in black African/African-Caribbean patients with POAG living in London. The study
      will look at the feasibility of recruitment for a proposed larger scale RCT and will also
      help the investigators to refine the methodology for the proposed trial in terms of outcome
      measures and analysis. It will also help the investigators to recruit a patient user group
      for input into the conduct and monitoring of the main trial.

      Information the study will provide

      The investigators are conducting this feasibility study in order to get an estimate of the
      likely recruitment rate for the main study and to collect information that will help the
      investigators to refine the outcome measures for the main study and to allow a valid
      calculation of the sample size needed for a definitive study to answer the primary research
      question. The investigators will use questionnaires to gather data on patients' quality of
      life for health economic analysis but it is also our hope that the questionnaires will give
      the investigators information on the perspectives of patients, including their preferences.
      This feasibility study will help the investigators to explore how they can gather useful
      information on the patient perspective.

      The feasibility study will also inform their planning for the main trial and data management
      and help them to develop their community engagement and recruitment strategies, including
      theri strategy for publicising the trial and enhancing recruitment. In addition, the
      investigators intend to use the feasibility study to recruit a patient representative group
      for input into the conduct and monitoring of the proposed main study.

      Risks and benefits The potential risks and benefits for patients participating in the
      feasibility study are similar to those for standard clinical care. All participants will have
      been identified as in need of glaucoma drainage surgery. Both trabeculectomy (currently as
      first line treatment) and Baerveldt tube surgery (currently as second line treatment) are in
      routine use for the treatment of POAG. Evidence on the beneficial effect of MMC is equivocal.
      First line treatment with Baerveldt tube surgery may be associated with less failure and
      complications than first line treatment by trabeculectomy but there is as yet no definitive
      evidence on this question that is specific to the population included in this study.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Single (Outcomes Assessor)
measure: Recruitment rate:
time frame: 6 months
description: The number of potential participants enrolled over a set time
measure: Success rate
time frame: 6 months
description: Eyes that have not failed and are not on supplemental medical therapy are considered complete successes
measure: Failure rate
time frame: 6 months
description: IOP >21 mmHg or not reduced by 20% below baseline on two consecutive follow-up visits
Additional glaucoma surgery
Loss of vision.
IOP <5 mmHg on two consecutive follow-up visits
measure: Complication rate
time frame: 6 months
measure: The number of extra unscheduled clinic visits and unplanned procedures
time frame: 6 months
measure: Loss to follow-up rate
time frame: 6 months
measure: Response rates to the self-report
time frame: 6 months
arm group label: Trabeculectomy with Mitomycin-C
arm group type: Active Comparator
description: The current standard surgical treatment for glaucoma remains trabeculectomy.
arm group label: Baerveldt tube surgery with Mitomycin C
arm group type: Active Comparator
description: It consists of a tube, draining aqueous humour to a plate
arm group label: Baerveldt tube surgery without Mitomycin C
arm group type: Active Comparator
description: It consists of a tube, draining aqueous humour to a plate
intervention type: Procedure
intervention name: Trabeculectomy
description: The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
arm group label: Trabeculectomy with Mitomycin-C
other name: Trabeculectomy with Mitomycin-C
intervention type: Device
intervention name: Baerveldt tube surgery
description: All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
arm group label: Baerveldt tube surgery with Mitomycin C
arm group label: Baerveldt tube surgery without Mitomycin C
other name: Baerveldt tube surgery with Mitomycin C
intervention type: Drug
intervention name: mitomycin-C
description: This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
arm group label: Baerveldt tube surgery with Mitomycin C
arm group label: Trabeculectomy with Mitomycin-C
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: K Sheng Lim, MD
role: Principal Investigator
affiliation: Guy's and St Thomas NHS Foundation Trust
last name: Sheng Lim, MD
phone: +442071884885
email: shenglim@gmail.com
last name: Stephanie Jones
phone: +442071884885
email: stephanie.jones@gstt.nhs.uk
facility: 
status: Recruiting
contact: 
contact backup: 
country: United Kingdom
responsible party type: Sponsor
mesh term: Glaucoma
mesh term: Glaucoma, Open-Angle
mesh term: Mitomycins
mesh term: Mitomycin
sharing ipd: No